In addition, CytRx is focused on rebuilding its institutional shareholder base, and to that end, will be increasing its participation in both industry and investor conferences, non-deal roadshows, and face-to-face meetings with certain prospective shareholders. "Working in oncology brings with it a unique set of rewards and challenges, including the ability and privilege to positively impact the lives of cancer patients and their families," said Steven A. Kriegsman, CytRx's Chairman and CEO. "While pharmaceutical research and development is difficult, lengthy and costly, we recognize that our goals need the support of shareholders who believe in our projects and objectives. Thank you for your continued support of CytRx and we look forward to keeping you updated on our progress." For more information about all of the ongoing CytRx projects, download the new corporate presentation which can be accessed here.